Sign In
Buy VERU
$2.25
-0.100 (-4.26%)
At Close: Jun 03, 2026
Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
11:30am, Monday, 05'th Dec 2022 GlobeNewswire Inc.
U.S. FDA reviewing EUA application for sabizabulin to treat hospitalized COVID-19 patients at high risk for ARDS
Veru Inc. (VERU) Q4 2022 Earnings Call Transcript
10:57am, Monday, 05'th Dec 2022
Veru Inc. (NASDAQ:VERU ) Q4 2022 Earnings Conference Call December 5, 2022 8:00 AM ET Company Participants Brandon Folkes - Cantor Fitzgerald Leland Gershell - Oppenheimer Chris Howerton - Jefferies Y
Veru Inc. (VERU) Reports Q4 Loss, Lags Revenue Estimates
09:02am, Monday, 05'th Dec 2022
Veru Inc. (VERU) delivered earnings and revenue surprises of -75.86% and 77.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Veru a Buy?
02:00pm, Friday, 02'nd Dec 2022 The Motley Fool
Or is it just another risky COVID stock?
Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022
01:30pm, Monday, 28'th Nov 2022 GlobeNewswire Inc.
MIAMI, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncolo
Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022
08:30am, Monday, 28'th Nov 2022
MIAMI, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology
Is It Too Late to Buy Veru Stock?
10:54pm, Wednesday, 23'rd Nov 2022 The Motley Fool
The negative impact of its COVID-19 program faltering will soon be in the past.
Is It Too Late to Buy Veru Stock?
05:54pm, Wednesday, 23'rd Nov 2022
The negative impact of its COVID-19 program faltering will soon be in the past.
Meridian Bioscience (VIVO) Q4 Earnings Surpass Estimates
02:15pm, Tuesday, 22'nd Nov 2022 Zacks Investment Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 33.33% and 2.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Shares of Veru Fell 10.33% on Monday
11:10pm, Monday, 21'st Nov 2022 The Motley Fool
Investors are concerned that approval for a COVID-19 therapy will be delayed or denied.
Why Shares of Veru Fell 10.33% on Monday
06:10pm, Monday, 21'st Nov 2022
Investors are concerned that approval for a COVID-19 therapy will be delayed or denied.
Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates
10:25pm, Monday, 14'th Nov 2022 Zacks Investment Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 7.41% and 13.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What You Might Have Missed: Eggs, Chicken and Apple
01:24pm, Saturday, 12'th Nov 2022 Investing.com
Why Veru Stock Was Losing One-Third of Its Value This Week
08:15pm, Friday, 11'th Nov 2022 The Motley Fool
The future of a top pipeline drug now looks much dimmer.
